Internal Medicine, Endocrinology, Diabetes, & Metabolism · Vineland, NJ
NPI
1285639732
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
0
Medicare group memberships
Hospitals
3
Hospital affiliations
2835 S Delsea Dr, Ste D
Vineland, NJ, 08360
Phone (856) 293-0305
Medicare paid, 2024
$321K
4,067 services
Medicare patients, 2024
926
Average age 73
Drug cost, 2024
$5.0M
10,513 prescriptions
Company payments, 2025
$1,930
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Helen L Slone was code 99232 (hospital e&m - subsequent), 1,924 times for 231 patients. In total Helen L Slone billed 4,067 services in 5 codes, and Medicare paid $321K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 1,924 | 231 | $60.05 | $116K |
| 99214 Office E&M - Established | Office | 1,779 | 688 | $93.63 | $167K |
| 99222 Hospital E&M - Initial | Facility | 261 | 226 | $99.22 | $26K |
| 99204 Office E&M - New | Office | 98 | 98 | $125.82 | $12K |
By year: 2022 $368K for 4,425 services; 2023 $386K for 4,517 services; 2024 $321K for 4,067 services.
Medicare prescription drug claims, 2024
In 2024, the drug Helen L Slone prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,819 prescriptions and refills. In total Helen L Slone wrote 10,513 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,819 | 4,910 | 474 | $29K |
| Jardiance Empagliflozin | 962 | 2,207 | 287 | $1.2M |
| Mounjaro Tirzepatide | 911 | 1,028 | 185 | $1.1M |
| Metformin Hcl Generic | 716 | 1,767 | 203 | $7,049 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 407 | 1,025 | 164 | $47K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 368 | 942 | 125 | $58K |
| Farxiga Dapagliflozin Propanediol | 345 | 772 | 91 | $418K |
| Glimepiride Generic | 320 | 835 | 97 | $2,518 |
| Trulicity Dulaglutide | 277 | 518 | 74 | $490K |
| Repaglinide Generic | 254 | 657 | 75 | $13K |
| Humalog Kwikpen U-100 Insulin Lispro | 253 | 631 | 86 | $77K |
| Synthroid Levothyroxine Sodium | 216 | 634 | 64 | $21K |
| Humalog Mix 75-25 Kwikpen Insulin Lispro Protamin/Lispro | 198 | 484 | 61 | $81K |
| Cabergoline Generic | 166 | 230 | 19 | $11K |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 139 | 275 | 43 | $13K |
Brand drugs: 5,822 claims; generic drugs: 3,623 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Helen L Slone $1,930 ($1,930 in general payments such as food, travel and fees) from 15 companies. The largest payer was CeQur Corporation with $645.
| Company | Payments | Amount |
|---|---|---|
| CeQur Corporation | 1 | $645 |
| Abbott Laboratories ABT | 44 | $418 |
| Dexcom, Inc. DXCM | 20 | $325 |
| Tandem Diabetes Care, Inc. TNDM | 5 | $91.36 |
| Madrigal Pharmaceuticals MDGL | 4 | $86.18 |
| Ascendis Pharma Endocrinology Inc ASND | 5 | $84.95 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $81.34 |
| Abbvie Inc. ABBV | 4 | $62.09 |
| Corcept Therapeutics CORT | 1 | $31.55 |
| Sequel Med Tech, LLC | 1 | $24.66 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.